Tofacitinib Market Report 2026

Tofacitinib Market Overview

• Tofacitinib market size has reached to $3.42 billion in 2025 • Expected to grow to $6.53 billion in 2030 at a compound annual growth rate (CAGR) of 14% • Growth Driver: Rising Ibd Cases Fuel Tofacitinib Market Growth • Market Trend: Topical Formulation For Atopic Dermatitis Marks A Milestone • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tofacitinib Market?

Tofacitinib is a medication used to treat ulcerative colitis and other rheumatic diseases such as, rheumatoid arthritis and ankylosing spondylitis. Tofacitinib is used in moderate to severely active ulcerative colitis after intolerance, a poor response, or a loss of response to biological therapy or conventional treatment. The main drug classes of tofacitinib are antirheumatic, Janus kinase inhibitor, and immunosuppressant. Antirheumatic refers to any medication used to treat rheumatism. The strengths involved are 5mg, 10mg, 11mg, and 22mg with oral and other routes of administration. The various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies for ulcerative colitis, rheumatoid arthritis, psoriasis, and others.

What Is The Tofacitinib Market Growth Forecast?

The tofacitinib market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to development of novel tofacitinib formulations, growing focus on precision medicine, increasing investment in biosimilars, expansion of online pharmacy channels, rising demand for immunosuppressants. Major trends in the forecast period include increasing adoption of targeted therapies, rising prevalence of ulcerative colitis and rheumatic diseases, shift towards personalized medicine, growing biopharmaceutical r&d investments, expansion of specialty pharmacies.

Global Tofacitinib Market Segmentation

1) By Drug Class: Antirheumatic, Janus Kinase Inhibitor, Immunosuppressant 2) By Strength: 5mg, 10mg, 11mg, 22mg 3) By Route Of Administration: Oral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By Application: Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Other Applications Subsegments: 1) By Antirheumatic: Conventional Synthetic Antirheumatics, Targeted Synthetic Antirheumatics 2) By Janus Kinase Inhibitor: JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors 3) By Immunosuppressant: Corticosteroids, Non-Steroidal Immunosuppressants

What Is The Driver Of The Tofacitinib Market?

The increasing number of patients with inflammatory bowel disease is expected to propel the growth of the tofacitinib market going forward. Inflammatory Bowel Disease (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract, primarily including Crohn's disease and ulcerative colitis. Tofacitinib plays an important role in the management of inflammatory bowel disease (IBD) patients by inhibiting Janus kinase (JAK) enzymes, offering relief from symptoms, and promoting mucosal healing. For instance, in June 2023, according to Crohn's and Colitis Canada, a Canada-based non-profit organization, over 322,600 Canadians were estimated to be living with inflammatory bowel diseases (IBD) in 2023, accounting for approximately 0.82% of the population. As the prevalence of IBD continues, it is estimated that around 470,000 Canadians will be living with IBD by 2035, approximately 1.1% of the population, or 1 in every 91 people in the country. Therefore, the increasing number of patients with inflammatory bowel disease is driving the growth of the tofacitinib industry.

Key Players In The Global Tofacitinib Market

Major companies operating in the tofacitinib market are Pfizer Inc, Beacon Pharmaceuticals Limited, Glenmark Pharmaceuticals LTD, Sun Pharmaceutical Industries Ltd, Zydus Lifesciences Ltd, Unichem Laboratories, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd, Lupin Limited, Aurobindo Pharma Limited, Cipla Inc, Dr. Reddys Laboratories Ltd, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited

Global Tofacitinib Market Trends and Insights

Major companies operating in the tofacitinib market are increasing their focus on introducing topical tofacitinib medications to gain a competitive edge in the market. Topical tofacitinib refers to a formulation of the medication tofacitinib that is designed for topical application on the skin. For instance, in June 2023, Intas Pharmaceuticals, an India-based pharmaceutical company, launched Tofacitinib Topical (JAKi) for the treatment of mild to moderate atopic dermatitis (AD) in India. This is the first JAK inhibitor approved for AD in India. A Phase III clinical study of TOFATAS (Tofacitinib Ointment 2% w/w) in atopic dermatitis patients in India demonstrated remarkable safety and efficacy. The launch of TOFATAS aims to bring new hope to patients suffering from AD, as there have been no approved topical JAK inhibitors in India until now.

What Are Latest Mergers And Acquisitions In The Tofacitinib Market?

In January 2025, Fiocruz, a Brazil-based public health institution focused on research, development, and production of vaccines and medicines, partnered with Pfizer Inc. to produce a generic version of Xeljanz (Tofacitinib) in Brazil. The partnership enables Fiocruz to broaden local availability of advanced rheumatoid arthritis therapies, while Pfizer leverages the collaboration to strengthen its presence and improve patient access in Brazil. Pfizer Inc. is a US-based manufacturer of tofacitinib.

Regional Insights

North America was the largest region in the tofacitinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tofacitinib Market?

The tofacitinib market consists of sales of Xeljanz and Xeljanz XR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tofacitinib Market Report 2026?

The tofacitinib market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tofacitinib industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.